CCT244747

Specifications / Handling

More Information
Product Details
Synonyms	(R)-3-((1-(Dimethylamino)propan-2-yl)oxy)-5-((4-methoxy-5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)amino)pyrazine-2-carbonitrile
Product Type	Chemical
Properties
Formula	C₂₀H₂₄N₈O₂
MW	408.5
CAS	1404095-34-6
Purity Chemicals	≥95%
Appearance	Solid.
Solubility	Soluble in DMSO.
Declaration	Manufactured by SynKinase.
Other Product Data	Target: CHK1 \| Kinase Group: CAMK \| Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key	IENLGMOXAQMNEH-CYBMUJFWSA-N
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

CCT244747 is a novel, potent, highly selective, orally active, ATP competitive CHK1 inhibitor. CCT244747 can inhibit cellular CHK1 activity with an IC₅₀ of 29-170nM. In multiple tumour cell models, this has the effect of significantly enhancing the cytotoxicity of several anticancer drugs (such as gemcitabine and irinotecan) and abrogating drug-induced S and G2 arrest.

Product References

Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors: M. Lainchbury, et al.; J. Med. Chem. 55, 10229 (2012)
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs: M.I. Walton, et al.; Clin. Cancer Res. 18, 5650 (2012)
The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment: I. Patties, et al.; J. Exp. Clin. Cancer Res. 38, 420 (2019)

Call	+41 61 926 6040
Fax	+41 61 926 6049